Similar articles

• Placebo group needed for interpretation of combination trial.

  El-Mallakh RS, Kaur G, Lippman S. El-Mallakh RS, et al. Am J Psychiatry. 2010 Aug;167(8):996; author reply 996-7. doi: 10.1176/appi.ajp.2010.10030453. Am J Psychiatry. 2010. PMID: 20693473 No abstract available.
• Continuation treatment with antidepressants in child and adolescent major depression.

  Ryan ND. Ryan ND. Am J Psychiatry. 2008 Apr;165(4):411-2. doi: 10.1176/appi.ajp.2008.08010115. Am J Psychiatry. 2008. PMID: 18381908 No abstract available.
• Suicidality and risk of suicide--definition, drug safety concerns, and a necessary target for drug development: a consensus statement.

  Meyer RE, Salzman C, Youngstrom EA, Clayton PJ, Goodwin FK, Mann JJ, Alphs LD, Broich K, Goodman WK, Greden JF, Meltzer HY, Normand SL, Posner K, Shaffer D, Oquendo MA, Stanley B, Trivedi MH, Turecki G, Beasley CM Jr, Beautrais AL, Bridge JA, Brown GK, Revicki DA, Ryan ND, Sheehan DV. Meyer RE, et al. J Clin Psychiatry. 2010 Aug;71(8):e1-e21. doi: 10.4088/JCP.10cs06070blu. J Clin Psychiatry. 2010. PMID: 20797373
• Critical appraisal of adverse effects reporting in the 'Treatment for Adolescents With Depression Study (TADS)'.

  Westergren T, Narum S, Klemp M. Westergren T, et al. BMJ Open. 2019 Mar 15;9(3):e026089. doi: 10.1136/bmjopen-2018-026089. BMJ Open. 2019. PMID: 30878988 Free PMC article. Review.
• Duloxetine: meta-analyses of suicidal behaviors and ideation in clinical trials for major depressive disorder.

  Acharya N, Rosen AS, Polzer JP, D'Souza DN, Perahia DG, Cavazzoni PA, Baldessarini RJ. Acharya N, et al. J Clin Psychopharmacol. 2006 Dec;26(6):587-94. doi: 10.1097/01.jcp.0000246216.26400.db. J Clin Psychopharmacol. 2006. PMID: 17110815